Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View ALNY insider activity ↗

ALNYALNYLAM PHARMACEUTICALS, INC.

THE LATEST REPORTED YEAR

The company reported a profit.

$313.75M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$3.71BYear ended December 31, 2025
Profit or loss$313.75MYear ended December 31, 2025
Cash from the business$524.08MYear ended December 31, 2025
Total assets$5.56BAs of June 30, 2026
Total liabilities$4.2BAs of June 30, 2026
Cash & equivalents$1.71BAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$74.91M
2018-12
$219.75M
2019-12
$492.85M
2020-12
$844.29M
2021-12
$1.04B
2022-12
$1.83B
2023-12
$2.25B
2024-12
$3.71B
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$3,713,937,000February 12, 202610-K ↗
January 1, 2024 – December 31, 2024$2,248,243,000February 12, 202610-K ↗
January 1, 2023 – December 31, 2023$1,828,292,000February 12, 202610-K ↗
January 1, 2022 – December 31, 2022$1,037,418,000February 13, 202510-K ↗
January 1, 2021 – December 31, 2021$844,287,000February 15, 202410-K ↗
January 1, 2020 – December 31, 2020$492,853,000February 11, 202110-K ↗
January 1, 2019 – December 31, 2019$219,750,000February 11, 202110-K ↗
January 1, 2018 – December 31, 2018$74,908,000February 11, 202110-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 8, 2026

Response SHA-256: bd72ebc4b5a116f8e743e4d6f33178d8af2533ff852a0cd94d52307715b0cbd0

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.